Construction of a Nomogram to Predict Overall Survival in Patients with Early-Onset Hepatocellular Carcinoma: A Retrospective Cohort Study

被引:0
|
作者
Kuang, Tianrui [1 ,2 ]
Ma, Wangbin [1 ,2 ]
Zhang, Jiacheng [1 ,2 ]
Yu, Jia [1 ,2 ]
Deng, Wenhong [1 ,2 ]
Dong, Keshuai [1 ,2 ]
Wang, Weixing [1 ,2 ]
机构
[1] Wuhan Univ, Renmin Hosp, Dept Gen Surg, Wuhan 430060, Peoples R China
[2] Wuhan Univ, Renmin Hosp, Cent Lab, Wuhan 430060, Peoples R China
基金
中国国家自然科学基金;
关键词
nomogram; early-onset hepatocellular carcinoma; overall survival; SEER database; online application; ALPHA-FETOPROTEIN; CANCER; MORTALITY; YOUNG;
D O I
10.3390/cancers15225310
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Hepatocellular carcinoma (HCC) is a severe global health concern, and it is increasingly jeopardizing younger individuals. Despite this, there is a lack of available tools for the prognosis estimation of early-onset HCC. In our study, we conducted a retrospective analysis of early-onset HCC (EO-LIHC) using data of the period from 2004 to 2018. We identified independent risk factors using a Cox regression analysis, including age, sex, AFP level, the grading and staging of the tumor, the size of the tumor, and whether the patient was receiving therapy like surgery and chemotherapy. We developed a predictive nomogram to estimate 1-, 3-, and 5-year survival rates of EO-LIHC patients and a user-friendly web-based survival prediction model tailored for these patients. These findings provide valuable insights for personalized care and treatment decisions for individuals with EO-LIHC.Abstract Hepatocellular carcinoma (HCC) is a widespread and impactful cancer which has pertinent implications worldwide. Although most cases of HCC are typically diagnosed in individuals aged >= 60 years, there has been a notable rise in the occurrence of HCC among younger patients. However, there is a scarcity of precise prognostic models available for predicting outcomes in these younger patients. A retrospective analysis was conducted to investigate early-onset hepatocellular carcinoma (EO-LIHC) using data from the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2018. The analysis included 1392 patients from the SEER database and our hospital. Among them, 1287 patients from the SEER database were assigned to the training cohort (n = 899) and validation cohort 1 (n = 388), while 105 patients from our hospital were assigned to validation cohort 2. A Cox regression analysis showed that age, sex, AFP, grade, stage, tumor size, surgery, and chemotherapy were independent risk factors. The nomogram developed in this study demonstrated its discriminatory ability to predict the 1-, 3-, and 5-year overall survival (OS) rates in EO-LIHC patients based on individual characteristics. Additionally, a web-based OS prediction model specifically tailored for EO-LIHC patients was created and validated. Overall, these advancements contribute to improved decision-making and personalized care for individuals with EO-LIHC.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Prognostic nomogram for hepatocellular carcinoma with radiofrequency ablation: a retrospective cohort study
    Lu, Zhenhua
    Sun, Zhen
    Liu, Chengyu
    Shi, Xiaolei
    Li, Rui
    Shao, Weiwei
    Zheng, Yangyang
    Li, Yao
    Song, Jinghai
    BMC CANCER, 2021, 21 (01)
  • [32] A nomogram to predict hyperkalemia in patients with hemodialysis: a retrospective cohort study
    Mei, Ziwei
    Chen, Jun
    Chen, Peipei
    Luo, Songmei
    Jin, Lie
    Zhou, Limei
    BMC NEPHROLOGY, 2022, 23 (01)
  • [33] A nomogram to predict hyperkalemia in patients with hemodialysis: a retrospective cohort study
    Ziwei Mei
    Jun Chen
    Peipei Chen
    Songmei Luo
    Lie Jin
    Limei Zhou
    BMC Nephrology, 23
  • [34] A novel nomogram based on the hematological prognosis risk scoring system can predict the overall survival of patients with hepatocellular carcinoma
    Lei, Kai
    Deng, Zhuofan
    Wang, Jiaguo
    Wang, Hongxiang
    Hu, Run
    Li, Yin
    Wang, Xingxing
    Xu, Jie
    You, Ke
    Liu, Zuojin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (16) : 14631 - 14640
  • [35] A novel nomogram based on the hematological prognosis risk scoring system can predict the overall survival of patients with hepatocellular carcinoma
    Kai Lei
    Zhuofan Deng
    Jiaguo Wang
    Hongxiang Wang
    Run Hu
    Yin Li
    Xingxing Wang
    Jie Xu
    Ke You
    Zuojin Liu
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 14631 - 14640
  • [36] Nomogram based on CMTM6 expression and clinical characteristics to predict postoperative overall survival in patients with hepatocellular carcinoma
    Dai, Mengjie
    Lan, Tao
    Chen, Hui
    Li, Xin
    Zhao, Zilong
    Jiang, Yingxue
    Yang, Long
    Wang, Songxiang
    HISTOLOGY AND HISTOPATHOLOGY, 2024, 39 (03) : 381 - 390
  • [37] Body Composition Features Predict Overall Survival in Patients With Hepatocellular Carcinoma
    Singal, Amit G.
    Zhang, Peng
    Waljee, Akbar K.
    Ananthakrishnan, Lakshmi
    Parikh, Neehar D.
    Sharma, Pratima
    Barman, Pranab
    Krishnamurthy, Venkataramu
    Wang, Lu
    Wang, Stewart C.
    Su, Grace L.
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2016, 7
  • [38] Development and validation of nomogram to predict overall survival and disease-free survival after surgical resection in elderly patients with hepatocellular carcinoma
    Tian, Yuan
    Wang, Yaoqun
    Wen, Ningyuan
    Lin, Yixin
    Liu, Geng
    Li, Bei
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [39] Nomogram to predict overall survival in patients with primary bladder neuroendocrine carcinoma: a population-based study
    Li, Sheng
    Liu, Xiaoqiang
    Liu, Weipeng
    Fu, Bin
    FUTURE ONCOLOGY, 2023, 18 (38) : 4171 - 4181
  • [40] Construction and verification of prognostic nomogram for early-onset esophageal cancer
    Liu, Xiaoxiao
    Guo, Wei
    Shi, Xiaobo
    Ke, Yue
    Li, Yuxing
    Pan, Shupei
    Jin, Yingying
    Wang, Yuchen
    Ruan, Qinli
    Ma, Hongbing
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2021, 21 (06) : 759 - 771